Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:16
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [31] Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma
    Veschi, Veronica
    Liu, Zhihui
    Voss, Ty C.
    Ozbun, Laurent
    Gryder, Berkley
    Yan, Chunhua
    Hu, Ying
    Ma, Anqi
    Jin, Jian
    Mazur, Sharlyn J.
    Lam, Norris
    Souza, Barbara K.
    Giannini, Giuseppe
    Hager, Gordon L.
    Arrowsmith, Cheryl H.
    Khan, Javed
    Appella, Ettore
    Thiele, Carol J.
    CANCER CELL, 2017, 31 (01) : 50 - 63
  • [32] Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
    Wu, Yong
    Xia, Lingfang
    Guo, Qinhao
    Zhu, Jun
    Deng, Yu
    Wu, Xiaohua
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5213 - 5223
  • [33] Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
    Neal, Adam
    Lai, Tiffany
    Singh, Tanya
    Rahseparian, Neela
    Grogan, Tristan
    Elashoff, David
    Scott, Peter
    Pellegrini, Matteo
    Memarzadeh, Sanaz
    CANCERS, 2021, 13 (23)
  • [34] Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis
    Kobayashi, Hiroshi
    Ogawa, Kenji
    Kawahara, Naoki
    Iwai, Kana
    Niiro, Emiko
    Morioka, Sachiko
    Yamada, Yuki
    FREE RADICAL RESEARCH, 2017, 51 (9-10) : 755 - 764
  • [35] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [36] AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
    Hojnik, Marko
    Suster, Natasa Kenda
    Smrkolj, Spela
    Sisinger, Damjan
    Grazio, Snjezana Frkovic
    Verdenik, Ivan
    Rizner, Tea Lanisnik
    CANCERS, 2022, 14 (03)
  • [37] Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
    Zhao, Li
    Corvigno, Sara
    Ma, Shaolin
    Celestino, Joseph
    Fleming, Nicole D.
    Hajek, Richard A.
    Ahumada, Adrian Lankenau
    Jennings, Nicholas B.
    Thompson, Erika J.
    Tang, Hongli
    Westin, Shannon N.
    Jazaeri, Amir A.
    Zhang, Jianhua
    Futreal, P. Andrew
    Sood, Anil K.
    Lee, Sanghoon
    CANCERS, 2022, 14 (15)
  • [38] Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer
    Silva, Romina
    Glennon, Kate
    Metoudi, Michael
    Moran, Bruce
    Salta, Sofia
    Slattery, Karen
    Treacy, Ann
    Martin, Terri
    Shaw, Jacqui
    Doran, Peter
    Lynch, Lydia
    Jeronimo, Carmen
    Perry, Antoinette S.
    Brennan, Donal J.
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 120 - 132
  • [39] Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness
    Wang, Zhihang
    Yang, Lili
    Huang, Zhenyu
    Li, Xuan
    Xiao, Juan
    Qu, Yinwei
    Huang, Lan
    Wang, Yan
    FRONTIERS IN GENETICS, 2022, 13
  • [40] Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models
    Taya, Manisha
    Hou, Xiaonan
    Veneris, Jennifer T.
    Kazi, Nina
    Larson, Melissa C.
    Maurer, Matthew J.
    Heinzen, Ethan P.
    Chen, Hao
    Lastra, Ricardo
    Oberg, Ann L.
    Weroha, S. John
    Fleming, Gini F.
    Conzen, Suzanne D.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2025, 36 (01)